Overview
As many as 80 percent of people with multiple sclerosis (MS) choose to incorporate non-traditional therapies into their treatment plan. These treatments may be in addition to (complementary) or instead of… read more
Overview
More than 40 percent of people with multiple sclerosis (MS) experience problems with speech at some point. Speech problems may take the form of dysarthria or dysphonia. Dysarthria, or speech disorder, could… read more
Overview
Ocrevus Zunovo is approved by the U.S. Food and Drug Administration (FDA) for treating relapsing forms of multiple sclerosis (MS), including clinically isolated syndrome, relapsing-remitting disease, and active…